7:18 PM
Nov 19, 2013
 |  BC Extra  |  Company News

Clovis acquires EOS

Clovis Oncology Inc. (NASDAQ:CLVS) acquired Ethical Oncology Science S.p.A. (Milan, Italy) for $200 million up front -- including $10 million in cash and about 3.7 million shares of Clovis stock -- plus up to $220 million in milestones. Clovis gains lucitanib ( E-3810), which...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >